CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Revenues:
Product sales	$ 2,443,388	$ 2,260,994	$ 2,648,657
License fee and other revenues	284,290	386,941	1,250,000
Research and development	363,572	585,312	1,754,434
Total revenues	3,091,250	3,233,247	5,653,091
Costs and Expenses:
Costs of goods sold	482,657	1,159,173	264,915
Research and development	51,776,395	53,492,471	41,735,888
Sales and marketing	873,154	1,027,139	768,871
General and administrative	29,108,777	6,562,555	9,102,926
Total costs and expenses	82,240,983	62,241,338	51,872,600
Operating loss	(79,149,733)	(59,008,091)	(46,219,509)
Changes in fair market value of warrant liabilities	(61,073,808)
Warrant related expenses	(7,649,395)
Interest expense	(5,479,821)	(5,479,821)	(2,090,750)
Interest and other income, net	430,595	337,901	245,705
Other financing expenses	(346,568)
Foreign currency transaction gain (loss), net	23,311	(39,538)	(1,188)
Loss before income tax	(153,245,419)	(64,189,549)	(48,065,742)
Income tax (expense) benefit	(20,867)	5,053,833	(58,229)
Net loss	(153,266,286)	(59,135,716)	(48,123,971)
Less: Net loss attributable to noncontrolling interest	(60,341)	(98,766)	(121,605)
Net loss attributable to Immunomedics, Inc. stockholders	$ (153,205,945)	$ (59,036,950)	$ (48,002,366)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted):	$ (1.47)	$ (0.62)	$ (0.51)
Weighted average shares used to calculate loss per common share (basic and diluted)	104,535,577	94,770,172	93,314,872
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	$ (62,085)	$ 1,192	$ (434,617)
Unrealized (loss) gain on securities available for sale	(108,399)	27,674	11,688
Other comprehensive (loss) income, net of tax:	(170,484)	28,866	(422,929)
Comprehensive loss	(153,436,770)	(59,106,850)	(48,546,900)
Less comprehensive loss attributable to noncontrolling interest	(60,341)	(98,766)	(121,605)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	$ (153,376,429)	$ (59,008,084)	$ (48,425,295)